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Background and purpose: A multi-center prospective randomized clinical trial has been performed investigating whether a reduction of the dose to the elective nodal sites in head and neck cancer delivered by intensity modulated radiotherapy (IMRT) would result in a reduction of late side effects without compromising tumor control. Materials and methods: Two hundred patients were included. The prescription dose to the elective nodal volumes was a normalized iso-effective dose in 2 Gy fractions (NID 2Gy ) of 50 Gy in the standard arm and of 40 Gy in the experimental arm. Late toxicity was scored at 6, 12, 18 and 24 months using the RTOG scoring system. Results: We observed a trend toward less dysphagia at 6 months in the experimental arm, however this was not confirmed after longitudinal analysis. Regarding moderate salivary gland toxicity we observed lower incidence of salivary gland toxicity Pgrade 1, at 6 (p = 0.01) and 18 months (p = 0.03).
Results: After two years of follow up, we did not observe significant differences in estimated local failure rate (14. 1% in the 40 Gy arm vs 14.4% in the 50 Gy arm), estimated regional failure rate (13.0% vs 5.5% in the 40 and the 50 Gy arm respectively), estimated metastatic recurrence (13.4% vs 18.5% in the 40 and the 50 Gy arm respectively), estimated disease-free survival (57.9% vs 65.3% in the 40 and the 50 Gy arm respectively) nor estimated overall survival (72.0% vs 73.2% in the 40 and the 50 Gy arm respectively). Conclusions: In our study population there was no statistically significant difference regarding survival and estimated recurrence rates between both arms of this study. We found a trend toward less dysphagia at 6 months (however not significant after longitudinal analysis) and found a significant reduction of any salivary gland toxicity at 6 and 18 months in the 40 Gy arm.
Ó 2016 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology xxx (2016) xxx-xxx Radiotherapy (RT) with curative intent for head and neck cancer (HNC) results in a significant amount of side effects due to unwanted doses in normal tissues surrounding the target volume [1, 2] . One of the most important late side effects limiting quality of life is swallowing dysfunction (dysphagia).
Following the introduction of more aggressive treatment strategies for HNC in the last decades, more attention has been addressed to late dysphagia [3] [4] [5] . Both concurrent chemotherapy and accelerated fractionation have been identified as significant predictive factors to develop dysphagia [3] [4] [5] 6] . The dose delivered to the pharyngeal constrictor muscles plays a crucial role in the development of severe late dysphagia [7] [8] [9] [10] [11] . Our research group demonstrated in a previous paper that a dose de-escalation to the elective lymph nodes in HNC results in significantly less dose to these functionally important structures and less severe dysphagia at 3 months following treatment [12] .
In this paper we report the results of a multi-center prospective randomized clinical trial that investigated whether a reduction of the dose to the elective nodal sites would result in a reduction of late dysphagia without compromising regional control. 
Material and methods
A prospective randomized multicenter non-inferiority phase III study was set up between 6 centers. Inclusion criteria were previously untreated, histologically proven squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, larynx or cervical lymph node metastases of unknown primary cancer (CUP). Patient workup was done according to institutional guidelines. T1-T2N0 were allowed, if prophylactic neck irradiation was performed. Patients were older than 18 years with a Karnofsky performance status P70%. The decision for primary (chemo-)RT with curative intent had to be made after a multidisciplinary meeting at each participating center. Concurrent chemotherapy was allowed, as well as pretreatment lymph node dissection. Local ethics committee approval was obtained before start of the study and all patients gave written informed consent. Patients were randomized to two treatment arms (experimental arm A and standard arm B). A total of 200 patients were included in the study (100 for each arm). To minimize the influence of center-specific parameters randomization was performed per center.
All macroscopically affected tumor sites were treated up to a normalized iso-effective dose in 2 Gy fractions (NID2Gy) of 70 Gy. Fractionation schedule and total dose delivered to the primary tumor and affected lymph nodes were left to the discretion of each individual center. An overview of the different fractionation schedules and CTV-PTV margins can be found in the preliminary analysis of this study [12] . For the elective nodal volumes, patients randomized in arm A (experimental arm) were treated up to a NID2Gy of 40 Gy. For arm B (control arm) the elective nodal volumes were treated up to a NID2Gy of 50 Gy (Fig. 1 ) [12] .
All patients were treated with IMRT using either an in-house developed extension of the GRATIS-software by Sherouse coupled to dose calculation using Pinnacle version 6.2b or the commercially available treatment planning systems (Eclipse Ò , Palo Alto; Tomotherapy High-art Ò , Madison) and delivered using 6 or 10 MV photons using either a step-and-shoot, a sliding window or rotational technique. Patient set-up and position verification was performed according to each center's discretion.
Late toxicity was scored at 6, 12, 18 and 24 months using the RTOG scoring system.
Assessment of HPV status
Since HPV status was not considered in the first paper, this was currently assessed [12] . For all patients with oropharyngeal tumors, formalin-fixed, paraffin-embedded (FFPE) tissue was centralized (University Hospital of Leuven) for HPV-status determination. HPV testing was performed using a previously validated algorithm using p16 immunohistochemistry (IHC) followed by HPV-polymerase chain reaction (PCR) [13] [14] [15] . A tumor was regarded as HPV related when both p16 IHC as well as HPV-PCR were positive.
For p16 IHC a purified mouse anti-human p16 antibody (G175-405, BD Pharmigen) was used. Sections were scored as p16 positive when clear p16 immunoreactivity was seen in at least 50% of cells [14] . DNA was extracted from PPFE sections using the QIAamp DNA FFPE Tissue kit. Concentration and purity where then defined with spectrophotometry. HPV status was determined with a PCR reaction using the GP5+/6+ primer set.
Endpoints of the study
The primary endpoint of the study was the rate of dysphagia at 6 months of follow-up.
Secondary endpoints of the study were: local, regional and distant control; recurrence and site of recurrence; overall, disease-free and disease-specific survival; stiffness of the neck; skin toxicity; salivary gland toxicity and mucosal integrity.
General considerations of the statistical analysis
Assuming a 70% rate of late dysphagia Pgrade 1 will be unacceptable and a 50% rate will be expected (a = 0.05, p = 0.8, two-tailed test) the power calculation of the study resulted in 200 eligible patients (100 patients per arm).
All tests were 2-sided and assessed at a significance level of 5%. Due to the exploratory nature of the study, no adjustments were made to the significance level to account for multiple testing. All analyses have been performed using SAS System for Windows (version 9.4).
Statistical analysis of the late toxicity endpoints
The following toxicity endpoints were assessed: dysphagia, stiffness of the neck, skin toxicity, salivary gland toxicity and mucosal integrity.
A chi-square test for trend was performed at each time-point to assess whether there was a statistically significant difference between the two randomized groups. Because these tests are susceptible to bias due to missing data, early withdrawals and/or early mortality, a longitudinal analyses using Generalized Estimating Equations (GEE) was also performed since it has been documented that GEE models can provide unbiased estimates even in such circumstances if the condition of Missingness at Random (MAR) holds. The above toxicity endpoints were analyzed using a GEE proportional odds model with an independent correlation matrix to account for the clustering of the data.
Primarily, the longitudinal proportional odds model includes a factor for randomized treatment, visit and their interaction. The inclusion of the interaction allows for the treatment effect to vary between visits. The effect of randomized treatment was estimated from the GEE model at each visit.
In addition, analyses were done for the probability of having severe (Pgrade 3) and moderate (Pgrade 1) toxicity. Since these are binary endpoints, the longitudinal analyses were done by means of a GEE logistic regression model.
Statistical analysis of outcome
Overall and disease-free survival was estimated using Kaplan-Meier methodology. Differences between treatments were assessed by means of a log-rank test.
Competing risk methodology was used for local, regional or distant failure, whereby death was considered to be a competing risk, to take the fact into account that patients who died cannot have a recurrence in the future. Event rates were estimated using cumulative incidence functions (CIF) and comparisons were made using Gray's test. 
Location of recurrences
In case of a regional recurrence, the recurrence was contoured on the CT study and rigidly co-registrated with the initial pretreatment CT study. Co-registration was done automatically using Eclipse Ò Treatment Planning system. If this was not accurate, manual registration was performed. To determine the exact location of recurrence the method described by Dawson et al. was used [13] . The recurrences were classified as 1) ''in-field," in which 95% or more of the recurrence volume (Vrecur) was within the 95% isodose; 2) ''marginal," in which 20% to 95% of Vrecur was within the 95% isodose; or 3) ''outside," in which less than 20% of Vrecur was within the 95% isodose.
Results

Patients
Between May 2008 and May 2011, 200 patients were included and randomized. Treatment characteristics of 7 patients could not be retrieved before close-out date of this analysis, yielding 193 patients for analysis (96 in the experimental arm and 97 in control arm). Patient characteristics are depicted in Table 1 .
The study included 83 patients with an oropharyngeal tumor; 41 in the 40 Gy and 42 in the 50 Gy arm. 17 patients (20,5%) of these 83 patients had an HPV positive tumor; 60 patients (72,5%) had an HPV negative tumor and 6 patients (7%) had an unknown HPV status. The summary of the result of the HPV assessment can be found in Table 1 .
Toxicity
Following a chi square test, we observed a trend toward less dysphagia at 6 months (p = 0.02) and at 24 months (p = 0.07) in the 40 Gy group. The difference in grade 2 dysphagia at 6 months stands out with 3.8% in the 40 Gy arm versus 20.8% in the 50 Gy arm. However, when accounting for early drop-outs and deaths using longitudinal analyses, no statistically significant differences regarding dysphagia between both treatment groups could be observed ( Table 2 ). The interaction between visit and treatment was found to be not significant (p = 0.80) and when removing the interaction from the model, the odds ratio between 40 Gy and 50 Gy for observing a lower grade of dysphagia was in favor of the 40 Gy group, however clearly not significant; 1.40 (95% confidence interval 0.93 to 2.10, p = 0.11). Furthermore, regarding moderate dysphagia (Pgrade1) or severe dysphagia (Pgrade 3), we did not observe significant differences between both groups.
We observed a lower incidence of any salivary gland toxicity (Pgrade 1), at 6 and 18 months (p = 0.01 and p = 0.04, respectively) in the 40 Gy arm (Table 3 ). This was confirmed by the longitudinal analyses (p = 0.01 and 0.03, respectively). The interaction between treatment and visit was found to be not significant (p = 0.14) and when removing the interaction from the model, the odds ratio between the 40 Gy group versus the 50 Gy group for having no salivary gland toxicity was in favor of the 40 Gy arm; 1.88 (95% CI 1.07 to 3.31, p = 0.03).
No significant difference between both groups was detected regarding stiffness of the neck, salivary gland toxicity Pgrade 3, skin problems and mucosal integrity.
Outcome
Median follow-up was 34.2 months (range 2.2-79.0). We did not observe significant differences in outcome and survival between both groups at 6, 12, 18 and 24 months ( Table 4) .
After 2 years, estimated overall survival was similar in both groups (72% and 73% in the 40 Gy and 50 Gy group, respectively Using a GEE proportional odds model including treatment, visit and their interaction, the interaction was found not significant (p = 0.8332). When dropped from the model, the odds ratio between 40 Gy and 50 Gy for observing a lower grade toxicity was 1.40 (95% confidence interval 0.93 to 2.10, p-value = 0.1088). Using a GEE logistic regression model including treatment, visit and their interaction, the interaction was found not significant (p = 0.1442). When dropped from the model, the odds ratio between 40 Gy and 50 Gy for having no salivary gland toxicity was 1.88 (95% confidence interval 1.07 to 3.31, p-value = 0.0281). For OS and DF, differences were assessed using a log-rank test. For LFR, RFR, LRFR and MR, differences between groups were assessed using Gray's testing, considering death as a competing risk. OS: overall survival; DFS: disease-free survival; LFR: local failure rate; RFR: regional failure rate; LRFR: loco-regional failure rate; MR: metastatic recurrence.
(p = 0.73)). Furthermore no statistically significant difference was found in the estimated disease free survival at 2 years (p = 0.41), although a lower rate was observed in the 40 Gy group (58%) in comparison with the rate in the 50 Gy group (65%). We did not observe statistically significant differences in estimated locoregional recurrence rates between both groups at 6, 12 and 24 months. However, after 2 years of follow-up, the cumulative incidence of locoregional recurrence was higher (24%) in the 40 Gy arm when compared to the 50 Gy arm (15%) (p = 0.14). The estimated local recurrence rate was 14% in both groups.
Regarding regional recurrences, we see a difference in estimated risk between both groups, however not significant (p = 0.08): 13% vs. 6% in the 40 Gy arm and 50 Gy arm at 2 years, respectively ( fig. 2 ). In total, 17 regional recurrences have been observed during follow-up ( Table 5 ). Three of seventeen (18%) occurred in the PTV elective (2 in the 40 Gy arm and 1 in the 50 Gy arm) whereas 12 regional recurrences were located in the high dose volume (11 in the GTV, 1 in the PTV). Two regional recurrences occurred outside the planning volume in the 40 Gy arm.
Of the 17 patients with regional recurrence, 6 underwent salvage neck dissection. Palliative chemotherapy was started in 4 patients, as salvage neck dissection was not considered to be advantageous because of synchronous metastases (n = 3) or an irresectable relapse (n = 1). No further therapy was provided in 7 patients because these patients opted not to be treated.
Regarding estimated metastatic risk, we observed no significant differences; however we observed a lower incidence (13.4%) in the 40 Gy arm when compared to the 50 Gy arm (18.5%) after 2 years of follow up (p = 0.25) ( fig. 3 ).
Discussion
In this paper we describe the late toxicity and outcome of a multicenter randomized controlled trial reducing the dose to the elective lymph nodes in patients treated for head and neck cancer.
The primary endpoint of this study was late dysphagia as this is the most important quality of life compromising toxicity after curative treatment of HNC [2] . Altered fractionation schedules, concomitant chemotherapy and oropharyngeal tumor location are associated with more dysphagia [6] . With the incidence of oropharyngeal carcinoma in the western world on the rise, the widespread use of concomitant chemoRT and the use of altered fractionation schedules, prevention of late dysphagia will be of upmost importance in optimizing the quality of life in these patients [16] [17] [18] [19] .
Our preliminary analysis demonstrated that a dose deescalation to the elective lymph nodes, significantly reduced the volume of the swallowing apparatus irradiated up to a high dose without compromising target coverage and dose homogeneity. Clinically this dose reduction resulted in significantly less grade P3 dysphagia in the de-escalated arm 3 months after treatment with similar LRC and DFS rates [12] . We also observed a better quality of life in the 40 Gy arm (unpublished data, recently submitted to Radiotherapy and Oncology).
The current updated results show a trend toward less late dysphagia, however not confirmed after longitudinal analysis. Furthermore, we observed significantly less moderate salivary gland toxicity in the 40 Gy arm at 6 and 18 months, confirmed after longitudinal analysis. This is a somewhat unexpected finding, since Fig. 2 . Cumulative incidence curves for regional recurrence. there was no significant difference between doses tot the parotid glands in both treatment arms, as published in our first paper. No significant difference between both groups was detected regarding stiffness of the neck, severe salivary gland toxicity, skin problems and mucosal integrity. A possible explanation for this is the fact that the high doses given to the PTV of the primary tumor were identical in both groups.
Outcome in terms of local, regional and distant control and survival did not differ significantly between the groups after two years of follow up. In the 40 Gy arm however, we observed a higher absolute number of all regional recurrences (i.e. in the elective neck as well as in pre-existing pathological lymph nodes). It was reassuring that there were only 2 regional recurrences in the elective neck outside the high-dose PTV in the 40 Gy arm and 1 in the 50 Gy arm. Obviously, these numbers are too small to conclude that more elective neck recurrences would occur when lowering the dose in the elective neck from 50 to 40 Gy NID 2Gy .
It could be hypothesized that lowering the dose for subclinical disease could result in less control and thereby in higher numbers of distant metastases [20] . We did not observe more distant metastases in the de-escalated group; on the contrary, a higher absolute number of patients had distant metastases in the 50 Gy group (not significant). This finding is reassuring with respect to the possibility to enhance occurrence of distant metastases when lowering the dose to the elective neck.
So far, no randomized data on dose de-escalation to the elective nodal volume in head and neck cancer were published. Therefore the choice of 40 Gy for our de-escalation arm was quite arbitrarily chosen, although supported by two non-randomized analyses [21, 22] .
We hereby present the first study that demonstrates the noninferiority of dose de-escalation in the elective neck to 40 Gy in terms of regional control in the elective neck. Meanwhile, a follow-up multicenter trial has been conducted comparing dose de-escalation in the elective neck using adaptive RT in reduced volumes of the elective neck in an attempt to further diminish treatment-induced toxicity. Combining data of both studies can give us more information on the safety of dose-reduction to the elective nodal volume.
Although the main purpose of the trial was to study the effect of a dose-reduction to 40 Gy-equivalent dose in the elective neck, a large heterogeneity remains between the treating centers in terms of fractionation schedules, dose prescription to the high-dose PTV, expansion margins from CTV to PTV, patient positioning protocols and the use of concurrent chemotherapy. In order to avoid confounding effects of this center-dependent heterogeneity, the trial randomization was performed per center.
Conclusions
Dose de-escalation to the elective nodal volume in HNC from a 50 to a 40 Gy-equivalent dose results in a trend toward less dysphagia at 6 months and less moderate salivary gland toxicity without significant differences in disease control or survival. (95% CI) 18.5% (11.3%, 27.1%) Fig. 3 . Cumulative incidence curves for metastatic risk.
